Delaware
|
22-2413505
|
|
(State
or Other Jurisdiction of
|
(IRS
Employer Identification Number)
|
|
Incorporation
or Organization)
|
07054
|
||
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Page
|
|
3
|
|
|
|
Condensed
Consolidated Balance Sheets as of September 30, 2008 (Unaudited)
and
December 31, 2007
|
4
|
|
|
Condensed
Consolidated Statements of Operations for the Three and Nine
Months Ended September 30, 2008 and 2007
(Unaudited)
|
5
|
|
|
Condensed
Consolidated Statements of Cash Flows for the Nine Months Ended September
30, 2008 and 2007 (Unaudited)
|
6
|
|
|
Notes
to Condensed Consolidated Financial Statements (Unaudited)
|
7
|
|
|
Item
2. Management's Discussion and Analysis of Financial Condition and
Results
of Operations
|
11
|
|
|
Item
3. Quantitative and Qualitative Disclosure about Market
Risk
|
15
|
|
|
Item
4T. Controls and Procedures
|
15
|
|
|
PART
II. OTHER INFORMATION
|
|
Item
1. Legal Proceedings
|
16
|
|
|
Item
2. Unregistered Sale of Equity Securities and Use of
Proceeds
|
16
|
|
|
Item
5. Other Information
|
16
|
|
|
Item
6. Exhibits
|
17
|
|
|
SIGNATURES
|
18
|
September
30, 2008
|
December
31, 2007
|
||||||
(Unaudited)
|
|||||||
Assets
|
|||||||
Current
assets
|
|||||||
Cash
and cash equivalents
|
$
|
1,251,399
|
$
|
2,525,641
|
|||
Restricted
cash
|
321,329
|
320,000
|
|||||
Other
receivables
|
1,033
|
397,868
|
|||||
Prepaid
expenses and other current assets
|
5,981
|
9,527
|
|||||
Total
assets
|
$
|
1,579,742
|
$
|
3,253,036
|
Liabilities
and Stockholders’ Equity
|
|||||||
Current
liabilities
|
|||||||
Accounts
payable
|
$
|
130,751
|
$
|
333,880
|
|||
Accrued
expenses
|
107,317
|
164,248
|
|||||
Accrued
payroll and related liabilities
|
17,262
|
897,248
|
|||||
Accrued
interest - related party
|
15,814
|
15,814
|
|||||
Total
liabilities
|
271,144
|
1,411,190
|
|||||
Commitments
and contingencies
|
|||||||
Stockholders’
Equity
|
|||||||
Preferred
stock - par value $.001 per share; authorized 1,000,000
shares;
200,000
shares designated Series A; 155,557 shares issued and
outstanding
(aggregate liquidation preference $280,003)
|
156
|
156
|
|||||
Common
stock - par value $.001 per share; authorized 750,000,000
shares;
33,047,161
shares issued and outstanding
|
33,048
|
33,048
|
|||||
Additional
paid-in capital
|
45,870,896
|
45,862,529
|
|||||
Accumulated
deficit
|
(44,053,887
|
)
|
(44,053,887
|
)
|
|||
Deficit
accumulated during the development stage
|
(541,615
|
)
|
—
|
||||
Total
stockholders’ equity
|
1,308,598
|
1,841,846
|
|||||
Total
liabilities and stockholders’ equity
|
$
|
1,579,742
|
$
|
3,253,036
|
For
the
Three
Months Ended September 30, 2008
|
For
the
Three
Months Ended September 30, 2007
|
For
the
Nine
Months Ended September 30, 2008
|
For
the
Nine
Months Ended September 30, 2007
|
||||||||||
Net
sales
|
$
|
—
|
$
|
744,643
|
$
|
—
|
$
|
2,323,214
|
|||||
Cost
of sales
|
—
|
361,652
|
—
|
1,024,615
|
|||||||||
Gross
margin
|
—
|
382,991
|
—
|
1,298,599
|
|||||||||
Operating
expenses:
|
|||||||||||||
Research
and development
|
—
|
72,002
|
236
|
239,500
|
|||||||||
Selling,
general and administrative expenses
|
129,230
|
561,402
|
564,277
|
1,845,414
|
|||||||||
Depreciation
expense
|
—
|
5,767
|
—
|
16,236
|
|||||||||
Total
operating expenses
|
129,230
|
639,171
|
564,513
|
2,101,150
|
|||||||||
Loss
from operations
|
(129,230
|
)
|
(256,180
|
)
|
(564,513
|
)
|
(802,551
|
)
|
|||||
Other
income
|
—
|
758
|
—
|
2,098
|
|||||||||
Interest
(expense) - related party
|
(4,137
|
)
|
(4,137
|
)
|
|||||||||
Interest
income/(expense)
|
9,246
|
(17,369
|
)
|
37,593
|
(48,965
|
)
|
|||||||
Loss
before income taxes
|
(119,984
|
)
|
(276,928
|
)
|
(526,920
|
)
|
(853,555
|
)
|
|||||
Income
tax expense
|
13,239
|
370
|
14,695
|
2,682
|
|||||||||
Net
loss
|
$
|
(133,223
|
)
|
$
|
(276,558
|
)
|
$
|
(541,615
|
)
|
$
|
(856,237
|
)
|
|
Per
share data:
|
|||||||||||||
Net
loss per common share
|
|||||||||||||
Basic
and diluted
|
$
|
0.00
|
$
|
(0.01
|
)
|
$
|
(0.02
|
)
|
$
|
(0.03
|
)
|
||
Weighted
average number of common shares outstanding
|
|||||||||||||
Basic
and diluted
|
33,047,161
|
32,785,565
|
33,047,161
|
32,785,565
|
For
the
Nine
Months Ended
September
30, 2008
|
For
the
Nine
Months Ended
September 30, 2007
|
||||||
Cash
flows from operating activities
|
|||||||
Net
loss
|
$
|
(541,615
|
)
|
$
|
(856,237
|
)
|
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|||||||
Depreciation
and amortization
|
—
|
281,707
|
|||||
Non-cash
stock-based compensation
|
8,367
|
139,989
|
|||||
Provision
for doubtful accounts
|
—
|
20,142
|
|||||
Provision
for inventory reserve
|
—
|
(29,777
|
)
|
||||
Interest
on notes payable
|
—
|
3,123
|
|||||
Interest
on notes payable - related party
|
-
|
3,915
|
|||||
Deferred
rent
|
—
|
2,251
|
|||||
Amortization
of deferred financing costs
|
—
|
24,525
|
|||||
Amortization
of debt discount
|
—
|
488
|
|||||
Interest
income on restricted cash
|
(1,329
|
)
|
—
|
||||
Changes
in operating assets and liabilities:
|
|||||||
Accounts
receivable
|
—
|
64,247
|
|||||
Other
receivables
|
396,835
|
—
|
|||||
Inventories
|
—
|
273,350
|
|||||
Prepaid
expenses and other current assets
|
3,546
|
13,121
|
|||||
Other
assets
|
—
|
10,085
|
|||||
Accounts
payable
|
(203,129
|
)
|
48,374
|
||||
Accrued
expenses
|
(56,931
|
)
|
(21,378
|
)
|
|||
Accrued
payroll and related liabilities
|
(879,986
|
)
|
4,099
|
||||
Deferred
income
|
—
|
(32,099
|
)
|
||||
Net
cash used in operating activities
|
(1,274,242
|
)
|
(50,075
|
)
|
|||
Cash
flow from investing activities
|
|||||||
Acquisition
of property and equipment
|
—
|
(1,379
|
)
|
||||
Capitalized
software expenditures
|
—
|
(439,899
|
)
|
||||
Net
cash used in investing activities
|
—
|
(441,278
|
)
|
||||
Cash
flows from financing activities
|
|||||||
Principal
payments on debt and capital leases
|
—
|
(1,891
|
)
|
||||
Advances
under notes payable
|
—
|
150,000
|
|||||
Advances
under notes payable - related parties
|
—
|
175,000
|
|||||
Borrowings
from revolving credit facility
|
395,269
|
||||||
Repayment
of revolving credit facility
|
—
|
(472,943
|
)
|
||||
Deferred
financing costs
|
(10,000
|
)
|
|||||
Net
cash provided by financing activities
|
—
|
235,435
|
|||||
Net
decrease in cash and cash equivalents
|
(1,274,242
|
)
|
(255,918
|
)
|
|||
Cash
and cash equivalents - beginning of period
|
2,525,641
|
265,936
|
|||||
Cash
and cash equivalents - end of period
|
$
|
1,251,399
|
$
|
10,018
|
|
For
the three months
ended
September 30,
|
For
the nine months
ended
September 30,
|
|||||||||||
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Cost
of Sales
|
$
|
—
|
$
|
851
|
$
|
—
|
$
|
3,860
|
|||||
Research
& Development
|
—
|
4,853
|
—
|
29,226
|
|||||||||
Selling,
General & Administrative
|
2,060
|
28,142
|
8,367
|
106,903
|
|||||||||
Totals
|
$
|
2,060
|
$
|
33,846
|
$
|
8,367
|
$
|
139,989
|
Nine
months ended September 30,
|
|||||||
2008
|
2007
|
||||||
Risk-free
interest rate
|
2.61-3.27
|
%
|
4.52%-5.05
|
%
|
|||
Dividend
yield
|
N/A
|
N/A
|
|||||
Expected
volatility range
|
227-233
|
%
|
202-224
|
%
|
|||
Expected
life in years
|
5
|
5
|
|||||
Expected
forfeiture rate (through term)
|
0
|
%
|
0
|
%
|
Options
|
Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Term
|
Aggregate
Intrinsic
Value
|
|||||||||
Outstanding
at January 1, 2008
|
5,490,407
|
$
|
0.27
|
2.75
years
|
|||||||||
Granted
|
52,500
|
$
|
0.06
|
4.67
years
|
|||||||||
Canceled
|
(2,650,003
|
)
|
$
|
0.44
|
3.43
years
|
||||||||
Outstanding
at September 30, 2008
|
2,892,904
|
$
|
0.12
|
0.95
years
|
$
|
413
|
|||||||
Exercisable
at September 30, 2008
|
2,810,404
|
$
|
0.11
|
0.91
years
|
$
|
413
|
·
|
our
ability to complete a combination with one or more target businesses;
|
·
|
our
success in retaining or recruiting, or changes required in, our officers
or directors prior to or following a business combination;
|
·
|
our
potential inability to obtain additional financing to complete a
business
combination;
|
·
|
a
limited pool of prospective target businesses;
|
·
|
a
potential change in control if we acquire one or more target businesses
for stock;
|
·
|
our
public securities’ limited liquidity and trading;
and
|
·
|
our
ongoing financial performance.
|
31.1
|
*
|
Certification
of Chief Executive Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
31.2
|
*
|
Certification
of Chief Financial Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
32.1
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
The Sarbanes-Oxley Act of 2002, of Chief Executive Officer
|
32.2
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
The Sarbanes-Oxley Act of 2002, of Chief Financial
Officer
|
CLACENDIX,
INC.
|
||
|
|
|
Date:
November
13, 2008
|
/S/
Norman E. Corn
|
|
Norman
E. Corn, Chief Executive Officer
|
/S/
Patrick E. Delaney
|
||
Patrick
E. Delaney, Chief Financial Officer
|
31.1
|
*
|
Certification
of Chief Executive Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
31.2
|
*
|
Certification
of Chief Financial Officer pursuant to Securities Exchange Act Rule
13a-14(a)
|
32.1
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
The Sarbanes-Oxley Act of 2002, of Chief Executive Officer
|
32.2
|
*
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
The Sarbanes-Oxley Act of 2002, of Chief Financial
Officer
|